-
1.发明授权Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them 有权甲基取代的1-（羧基烷基） - 环戊基 - 羰基氨基 - 苯并氮杂-N-乙酸化合物，其制备方法和中间产物以及含有它们的药物组合物公开(公告)号：US07427611B2
公开(公告)日：2008-09-23
申请号：US11404775
申请日：2006-04-17
申请人： Dagmar Hoeltje , Yvan Fischer , Dieter Ziegler , Michael Weske , Katrin Michaelis , Yasmin Karimi-Nejad , Josef Messinger , Axel Pahl , Constanze Hoefer , Hrissanthi Ikonomidou , Lechoslaw Turski
发明人： Dagmar Hoeltje , Yvan Fischer , Dieter Ziegler , Michael Weske , Katrin Michaelis , Yasmin Karimi-Nejad , Josef Messinger , Axel Pahl , Constanze Hoefer , Hrissanthi Ikonomidou , Lechoslaw Turski
IPC分类号： C07D223/16 , A61K38/05 , A61P9/12
CPC分类号： C07D223/16 , C07D401/12 , C07K5/0222 , C07K5/06139
摘要： Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula I, wherein the substituents R1, R2, R3 and R4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
摘要翻译： 具有对应于式I的中性内肽酶（NEP）和/或人可溶内肽酶（hSEP）抑制活性的化合物，其中取代基R 1，R 2，R SUP > 3和R 4具有说明书中给出的含义，并且还含有这些化合物的药物组合物，特别是适用于治疗或抑制心血管疾病，性功能障碍和/或不利条件的药物组合物 与凋亡相关。
-
2.发明申请Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them 有权酰胺甲基取代的1-（羧基烷基）环戊基 - 羰基氨基 - 苯并氮杂-N-乙酸化合物，其制备方法和中间产物以及含有它们的药物组合物公开(公告)号：US20050119247A1
公开(公告)日：2005-06-02
申请号：US10948843
申请日：2004-09-24
申请人： Dagmar Hoeltje , Yvan Fischer , Dieter Ziegler , Michael Weske , Katrin Michaelis , Yasmin Karimi-Nejad , Josef Messinger , Axel Pahl , Constanze Hoefer , Hrissanthi Ikonomidou , Lechoslaw Turski
发明人： Dagmar Hoeltje , Yvan Fischer , Dieter Ziegler , Michael Weske , Katrin Michaelis , Yasmin Karimi-Nejad , Josef Messinger , Axel Pahl , Constanze Hoefer , Hrissanthi Ikonomidou , Lechoslaw Turski
CPC分类号： C07K5/06139 , C07K5/0222
摘要： Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula 1, wherein the substituents R1, R2, R3 and R4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
摘要翻译： 具有对应于式1的中性内肽酶（NEP）和/或人可溶内肽酶（hSEP）抑制活性的化合物，其中取代基R 1，R 2，R SUP > 3和R 4具有说明书中给出的含义，并且还含有这些化合物的药物组合物，特别是适用于治疗或抑制心血管疾病，性功能障碍和/或不利条件的药物组合物 与凋亡相关。
-
3.发明申请Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them 有权甲基取代的1-（羧基烷基） - 环戊基 - 羰基氨基 - 苯并氮杂-N-乙酸化合物，其制备方法和中间产物以及含有它们的药物组合物公开(公告)号：US20060281732A1
公开(公告)日：2006-12-14
申请号：US11404775
申请日：2006-04-17
申请人： Dagmar Hoeltje , Yvan Fischer , Dieter Ziegler , Michael Weske , Katrin Michaelis , Yasmin Karimi-Nejad , Josef Messinger , Axel Pahl , Constanze Hoefer , Hrissanthi Ikonomidou , Lechoslaw Turski
发明人： Dagmar Hoeltje , Yvan Fischer , Dieter Ziegler , Michael Weske , Katrin Michaelis , Yasmin Karimi-Nejad , Josef Messinger , Axel Pahl , Constanze Hoefer , Hrissanthi Ikonomidou , Lechoslaw Turski
IPC分类号： A61K31/55
CPC分类号： C07D223/16 , C07D401/12 , C07K5/0222 , C07K5/06139
摘要： Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula I, wherein the substituents R1, R2, R3 and R4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
摘要翻译： 具有对应于式I的中性内肽酶（NEP）和/或人可溶内肽酶（hSEP）抑制活性的化合物，其中取代基R 1，R 2，R SUP > 3和R 4具有说明书中给出的含义，并且还含有这些化合物的药物组合物，特别是适用于治疗或抑制心血管疾病，性功能障碍和/或不利条件的药物组合物 与凋亡相关。
-
公开(公告)号：US07452875B2
公开(公告)日：2008-11-18
申请号：US11833430
申请日：2007-08-03
申请人： Dagmar Hoeltje , Yvan Fischer , Dieter Ziegler , Michael Weske , Katrin Michaelis , Yasmin Karimi-Nejad , Josef Messinger , Axel Pahl , Constanze Hoefer , Hrissanthi Ikonomidou , Lechoslaw Turski
发明人： Dagmar Hoeltje , Yvan Fischer , Dieter Ziegler , Michael Weske , Katrin Michaelis , Yasmin Karimi-Nejad , Josef Messinger , Axel Pahl , Constanze Hoefer , Hrissanthi Ikonomidou , Lechoslaw Turski
IPC分类号： C07D223/16 , A61K38/05 , A61P9/12
CPC分类号： C07D223/16 , C07D401/12 , C07K5/0222 , C07K5/06139
摘要： Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula I, wherein the substituents R1, R2, R3 and R4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
-
5.发明授权Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them 有权酰胺甲基取代的1-（羧基烷基）环戊基 - 羰基氨基 - 苯并氮杂-N-乙酸化合物，其制备方法和中间产物以及含有它们的药物组合物公开(公告)号：US07410962B2
公开(公告)日：2008-08-12
申请号：US11773231
申请日：2007-07-03
申请人： Dagmar Hoeltje , Yvan Fischer , Dieter Ziegler , Michael Weske , Katrin Michaelis , Yasmin Karimi-Nejad , Josef Messinger , Axel Pahl , Constanze Hoefer , Hrissanthi Ikonomidou , Lechoslaw Turski
发明人： Dagmar Hoeltje , Yvan Fischer , Dieter Ziegler , Michael Weske , Katrin Michaelis , Yasmin Karimi-Nejad , Josef Messinger , Axel Pahl , Constanze Hoefer , Hrissanthi Ikonomidou , Lechoslaw Turski
IPC分类号： C07D223/16 , A61K38/05 , A61P9/12
CPC分类号： C07K5/06139 , C07K5/0222
摘要： Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula I, wherein the substituents R1, R2, R3 and R4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
摘要翻译： 具有对应于式I的中性内肽酶（NEP）和/或人可溶内肽酶（hSEP）抑制活性的化合物，其中取代基R 1，R 2，R SUP > 3和R 4具有说明书中给出的含义，并且还含有这些化合物的药物组合物，特别是适用于治疗或抑制心血管疾病，性功能障碍和/或不利条件的药物组合物 与凋亡相关。
-
6.发明申请AMIDOMETHYL-SUBSTITUTED 1-(CARBOXYALKYL) CYCLOPENTYL-CARBONYLAMINO-BENZAZEPINE-N-ACETIC ACID COMPOUNDS, PROCESS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM 有权氨基取代的1-（羧基甲基）环戊烯基 - 亚磺酰氨基 - 苯甲腈-N-乙酸化合物，其制备和其包含它们的药物组合物的方法和中间产物公开(公告)号：US20070265244A1
公开(公告)日：2007-11-15
申请号：US11773231
申请日：2007-07-03
申请人： Dagmar Hoeltje , Yvan Fischer , Dieter Ziegler , Michael Weske , Katrin Michaelis , Yasmin Karimi-Nejad , Josef Messinger , Axel Pahl , Constanze Hoefer , Hrissanthi Ikonomidou , Lechoslaw Turski
发明人： Dagmar Hoeltje , Yvan Fischer , Dieter Ziegler , Michael Weske , Katrin Michaelis , Yasmin Karimi-Nejad , Josef Messinger , Axel Pahl , Constanze Hoefer , Hrissanthi Ikonomidou , Lechoslaw Turski
IPC分类号： A61K31/55 , A61P9/00 , C07D487/00
CPC分类号： C07K5/06139 , C07K5/0222
摘要： Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula I, wherein the substituents R1, R2, R3 and R4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
摘要翻译： 具有对应于式I的中性内肽酶（NEP）和/或人可溶内肽酶（hSEP）抑制活性的化合物，其中取代基R 1，R 2，R SUP > 3和R 4具有说明书中给出的含义，并且还含有这些化合物的药物组合物，特别是适用于治疗或抑制心血管疾病，性功能障碍和/或不利条件的药物组合物 与凋亡相关。
-
7.发明申请Amidomethyl-Substituted 1-(Carboxyalkyl) Cyclopentyl-Carbonylamino-Benzazepine-N-Acetic Acid Compounds, Process and Intermediate Products for Their Preparation and Pharmaceutical Compositions Containing Them 有权酰基甲基取代的1-（羧基烷基）环戊基 - 羰基氨基 - 苯并氮杂-N-乙酸化合物，其制备方法和中间体产品及含有它们的药物组合物公开(公告)号：US20080085889A1
公开(公告)日：2008-04-10
申请号：US11833430
申请日：2007-08-03
申请人： Dagmar Hoeltje , Yvan Fischer , Dieter Ziegler , Michael Weske , Katrin Michaelis , Yasmin Karimi-Nejad , Josef Messinger , Axel Pahl , Constanze Hoefer , Hrissanthi Ikonomidou , Lechoslaw Turski
发明人： Dagmar Hoeltje , Yvan Fischer , Dieter Ziegler , Michael Weske , Katrin Michaelis , Yasmin Karimi-Nejad , Josef Messinger , Axel Pahl , Constanze Hoefer , Hrissanthi Ikonomidou , Lechoslaw Turski
IPC分类号： A61K31/55 , A61P25/28 , C07D487/00
CPC分类号： C07D223/16 , C07D401/12 , C07K5/0222 , C07K5/06139
摘要： Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula I, wherein the substituents R1, R2, R3 and R4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
摘要翻译： 具有对应于式I的中性内肽酶（NEP）和/或人可溶内肽酶（hSEP）抑制活性的化合物，其中取代基R 1，R 2，R SUP > 3和R 4具有说明书中给出的含义，并且还含有这些化合物的药物组合物，特别是适用于治疗或抑制心血管疾病，性功能障碍和/或不利条件的药物组合物 与凋亡相关。
-
8.发明授权Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them 有权酰胺甲基取代的1-（羧基烷基）环戊基 - 羰基氨基 - 苯并氮杂-N-乙酸化合物，其制备方法和中间产物以及含有它们的药物组合物公开(公告)号：US07262184B2
公开(公告)日：2007-08-28
申请号：US10948843
申请日：2004-09-24
申请人： Dagmar Hoeltje , Yvan Fischer , Dieter Ziegler , Michael Weske , Katrin Michaelis , Yasmin Karimi-Nejad , Josef Messinger , Axel Pahl , Constanze Hoefer , Hrissanthi Ikonomidou , Lechoslaw Turski
发明人： Dagmar Hoeltje , Yvan Fischer , Dieter Ziegler , Michael Weske , Katrin Michaelis , Yasmin Karimi-Nejad , Josef Messinger , Axel Pahl , Constanze Hoefer , Hrissanthi Ikonomidou , Lechoslaw Turski
IPC分类号： C07D223/16 , A61P9/12 , A61K38/05
CPC分类号： C07K5/06139 , C07K5/0222
摘要： Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula 1, wherein the substituents R1, R2, R3 and R4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
摘要翻译： 具有对应于式1的中性内肽酶（NEP）和/或人可溶内肽酶（hSEP）抑制活性的化合物，其中取代基R 1，R 2，R SUP > 3和R 4具有在说明书中给出的含义，并且还含有这些化合物的药物组合物，特别是适用于治疗或抑制心血管疾病，性功能障碍和/或不利条件的药物组合物 与凋亡相关。
-
9.发明申请Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders 有权中性内肽酶（NEP）和人类可溶性内肽酶（hSEP）抑制剂用于预防和治疗神经退行性疾病公开(公告)号：US20050153936A1
公开(公告)日：2005-07-14
申请号：US11030043
申请日：2005-01-07
IPC分类号： A61K31/55 , A61K31/553 , A61K31/554 , A61K31/675
CPC分类号： A61K31/675 , A61K31/55 , A61K31/553 , A61K31/554
摘要： The invention relates to a novel use of known benzazepine, benzoxazepine, benzo-thiazepine-N-acetic acid and phosphono-substituted benzazepinone derivatives having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity. The compounds of the invention are useful for the preparation of pharmaceutical compositions for prophylaxis and treatment of neurodegenerative disorders. The compounds of the invention are known from the European patents EP 0 733 642 and EP 0 916 679, and can be described by the general formulae (1): wherein the symbols have the meanings as given above in the description.
摘要翻译： 本发明涉及已知的苯并氮杂，苯并氧氮杂，苯并硫氮杂-N-乙酸和具有中性肽链内切酶（NEP）和（或）可溶性内肽酶（hSEP）抑制活性的膦酰取代苯并氮杂酮衍生物的新用途。 本发明的化合物可用于制备用于预防和治疗神经变性疾病的药物组合物。 本发明的化合物可以从欧洲专利EP 0 733 642和EP 0 916 679中得知，并且可以由通式（1）描述：其中符号具有上面在说明书中给出的含义。
-
10.发明授权Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders 有权中性内肽酶（NEP）和人类可溶性内肽酶（hSEP）抑制剂用于预防和治疗神经退行性疾病公开(公告)号：US07232813B2
公开(公告)日：2007-06-19
申请号：US11030043
申请日：2005-01-07
IPC分类号： A61P25/00
CPC分类号： A61K31/675 , A61K31/55 , A61K31/553 , A61K31/554
摘要： The invention relates to a novel use of known benzazepine, benzoxazepine, benzo-thiazepine-N-acetic acid and phosphono-substituted benzazepinone derivatives having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity. The compounds of the invention are useful for the preparation of pharmaceutical compositions for prophylaxis and treatment of neurodegenerative disorders.The compounds of the invention are known from the European patents EP 0 733 642 and EP 0 916 679, and can be described by the general formulae (1): wherein the symbols have the meanings as given above in the description.
摘要翻译： 本发明涉及已知的苯并氮杂，苯并氧氮杂，苯并硫氮杂-N-乙酸和具有中性肽链内切酶（NEP）和（或）可溶性内肽酶（hSEP）抑制活性的膦酰取代苯并氮杂酮衍生物的新用途。 本发明的化合物可用于制备用于预防和治疗神经变性疾病的药物组合物。 本发明的化合物可以从欧洲专利EP 0 733 642和EP 0 916 679中得知，并且可以由通式（1）描述：其中符号具有上面在说明书中给出的含义。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.047 秒)